6-Chlor-2-nitro-ethyl-benzol | 91862-20-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-Chlor-2-nitro-ethyl-benzol
• 英文别名: 1-Chloro-2-ethyl-3-nitrobenzene
• CAS: 91862-20-3
• 化学式: C₈H₈ClNO₂
• 分子量: 185.61
• InChiKey: TZTOKGXTDWNPFC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS
  申请人：ZAVERI NURULAIN T.

  公开号：US20110172264A1

  公开（公告）日：2011-07-14

  Provided herein are novel and selective high affinity α3β4 nicotinic acetylcholine receptor ligands and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, drug addiction or pain using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods for modulating a nicotinic acetylcholine receptor (nAChR). In still other embodiments, provided herein are methods of selectively antagonizing receptors such as, for example, the α3β4 nicotinic acetylcholine receptor using the compounds and compositions disclosed herein.

  本文提供了新颖且选择性高亲和力的α3β4尼古丁乙酰胆碱受体配体及其制药组合物。在其他实施例中，本文提供了利用本文披露的化合物和组合物治疗、预防或改善各种医学疾病的方法，例如药物成瘾或疼痛。在其他实施例中，本文提供了调节尼古丁乙酰胆碱受体（nAChR）的方法。在其他实施例中，本文提供了利用本文披露的化合物和组合物选择性拮抗受体的方法，例如α3β4尼古丁乙酰胆碱受体。
• Verfahren zur Herstellung von halogenierten aromatischen primären Aminen
  申请人：CIBA-GEIGY AG

  公开号：EP0325892B1

  公开（公告）日：1993-02-03
• ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS
  申请人：Antabio SAS

  公开号：EP3008045B1

  公开（公告）日：2018-05-09
• Antibacterial Thiazolecarboxylic Acids
  申请人：ANTABIO SAS

  公开号：US20160272601A1

  公开（公告）日：2016-09-22

  Compounds of general formula (I): wherein R 1 , R 11 , Y, R 2 , n and A are as defined herein are useful as inhibitors or metallo-β-lactamase (MBL) enzymes and can be used for reducing or removing antibiotic resistance in bacteria.
• PKM2 MODULATORS AND METHODS FOR THEIR USE
  申请人：Tolero Pharmaceuticals, Inc.

  公开号：US20170015631A1

  公开（公告）日：2017-01-19

  Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.